Clinical Trial Update: Phase Ib/II Trial of Cladribine/Ruxolitinib/Venetoclax in Patients With Relapsed/Refractory T-cell Prolymphocytic Leukemia [Phase 1, Phase 2]

View source ↗

Summary

This clinical trials entry describes a Phase Ib/II study evaluating a triplet regimen of cladribine, ruxolitinib, and venetoclax in relapsed or refractory T-cel…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• T-cell Prolymphocytic Leukemia

Drugs mentioned

• Cladribine (cladribine)
• Ruxolitinib (ruxolitinib)
• Venetoclax (venetoclax)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: T-cell Prolymphocytic Leukemia, Refractory T-Cell Prolymphocytic Leukemia | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING